{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T12:14:13Z","timestamp":1778933653886,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020869","name":"AstraZeneca Kabushiki Kaisha","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Asia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacasi.2026.01.014","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T01:58:26Z","timestamp":1773453506000},"page":"651-661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment"],"prefix":"10.1016","volume":"6","author":[{"given":"Kei","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyo","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyosung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Hiroki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Koga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacasi.2026.01.014_bib1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1253\/circj.CJ-22-0023","article-title":"10-year trends of antithrombotic therapy status and outcomes in Japanese atrial fibrillation patients \u2013 the Fushimi AF Registry","volume":"86","author":"Akao","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2026.01.014_bib2","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacasi.2026.01.014_bib3","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","article-title":"2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Tomaselli","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.01.014_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.thromres.2023.03.010","article-title":"Bleeding related to oral anticoagulants: trends in US emergency department visits, 2016-2020","volume":"225","author":"Geller","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacasi.2026.01.014_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1253\/circrep.CR-24-0061","article-title":"Patient outcomes in very elderly patients with non-valvular atrial fibrillation \u2013 ANAFIE registry","volume":"6","author":"Suzuki","year":"2024","journal-title":"Circ Rep"},{"key":"10.1016\/j.jacasi.2026.01.014_bib6","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1253\/circj.CJ-23-0143","article-title":"Relationship between direct oral anticoagulant doses and clinical outcomes in elderly patients with non-valvular atrial fibrillation \u2013 ANAFIE registry sub-analysis","volume":"87","author":"Akao","year":"2023","journal-title":"Circ J"},{"key":"10.1016\/j.jacasi.2026.01.014_bib7","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for factor Xa inhibitor\u2013associated acute intracerebral hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.01.014_bib8","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1161\/STROKEAHA.120.030565","article-title":"Hemostatic efficacy and anti-FXa (factor Xa) reversal with andexanet alfa in intracranial hemorrhage: ANNEXA-4 substudy","volume":"52","author":"Demchuk","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jacasi.2026.01.014_bib9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.01.014_bib10","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","article-title":"Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors","volume":"380","author":"Connolly","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.01.014_bib11","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.01.014_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5551\/jat.64223","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity: prespecified subgroup analysis of the ANNEXA-4 study in Japan","volume":"31","author":"Toyoda","year":"2024","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacasi.2026.01.014_bib13","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacasi.2026.01.014_bib14","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1161\/CIRCULATIONAHA.121.057844","article-title":"Final study report of andexanet alfa for major bleeding with factor Xa inhibitors","volume":"147","author":"Milling","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacasi.2026.01.014_bib15","article-title":"Epidemiology of intracerebral hemorrhage: a systematic review and meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Front Neurol"},{"key":"10.1016\/j.jacasi.2026.01.014_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajem.2023.07.042","article-title":"Real world utilization of andexanet alfa in the management of oral factor Xa inhibitor-associated gastrointestinal bleeding","volume":"73","author":"Brown","year":"2023","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.jacasi.2026.01.014_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/fca-2020-0073","article-title":"Real-world management of oral factor Xa inhibitor-related bleeds with reversal or replacement agents including andexanet alfa and four-factor prothrombin complex concentrate: a multicenter study","volume":"17","author":"Coleman","year":"2021","journal-title":"Future Cardiol"},{"key":"10.1016\/j.jacasi.2026.01.014_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106070","article-title":"An 18-month single-center observational study of real-world use of andexanet alfa in patients with factor Xa inhibitor associated intracranial hemorrhage","volume":"195","author":"Giovino","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jacasi.2026.01.014_bib19","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1016\/j.jacc.2021.04.061","article-title":"Meta-analysis of reversal agents for severe bleeding associated with direct oral anticoagulants","volume":"77","author":"Gomez-Outes","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacasi.2026.01.014_bib20","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/08971900221125516","article-title":"Real-world reversal of factor Xa inhibition in the setting of major life-threatening bleeding or urgent surgery","volume":"37","author":"Schmidt","year":"2024","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.jacasi.2026.01.014_bib21","article-title":"Real-world observational review of andexanet alfa prescribing and utilization outcomes at a community teaching hospital","volume":"3","author":"Sobolewski","year":"2021","journal-title":"Crit Care Explor"},{"key":"10.1016\/j.jacasi.2026.01.014_bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11239-023-02820-y","article-title":"Real-world clinical outcomes among US veterans with oral factor Xa inhibitor-related major bleeding treated with andexanet alfa or 4-factor prothrombin complex concentrate","volume":"56","author":"Sutton","year":"2023","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacasi.2026.01.014_bib23","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1038\/s41598-024-55500-z","article-title":"Mortality after major bleeding in Asian atrial fibrillation patients receiving different direct oral anticoagulants: a nationwide, propensity score study","volume":"14","author":"Yu","year":"2024","journal-title":"Sci Rep"}],"container-title":["JACC: Asia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772374726000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T11:43:13Z","timestamp":1778931793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772374726000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2772374726000517"],"URL":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.01.014","relation":{},"ISSN":["2772-3747"],"issn-type":[{"value":"2772-3747","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Andexanet Alfa for Life-Threatening Bleeding Following Factor Xa Inhibitor Treatment","name":"articletitle","label":"Article Title"},{"value":"JACC: Asia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacasi.2026.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}